ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
디발프로엑스나트륨 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 CAGR 7.2%로 26억 달러 규모에 이를 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 간질 유병률 증가, 양극성 장애 발생률 증가, 편두통 진단율 증가, 신경 질환에 취약한 노인 인구의 증가, 의료 서비스 접근성 확대 등에 기인합니다. 이 시기의 주요 동향으로는 약물 제제법의 발전, 중추신경계(CNS) 질환에 대한 연구 증가, 약물전달 시스템의 혁신, 간질 및 양극성 장애 진단 도구의 강화, 표적 치료를 위한 바이오마커의 개발 등을 들 수 있습니다.
신경질환의 유병률 증가는 향후 디발프로엑스나트륨 시장의 성장을 견인할 것으로 예상됩니다. 신경질환은 뇌, 척수, 신경에 영향을 미쳐 근력저하, 발작, 인지장애 등의 기능장애 및 증상을 유발하는 질환입니다. 평균 수명이 길어짐에 따라 고령화 사회는 알츠하이머병, 파킨슨병 등 노년기에 발병하기 쉬운 질환의 영향을 받기 쉬워지고 있습니다. 디발프로엑스나트륨은 뇌의 전기적 활동을 안정시키고 발작을 예방하며, 간질이나 양극성 장애 등에서 흔히 나타나는 기분 저하를 조절함으로써 신경질환 관리에 중요한 역할을 합니다. 예를 들어, 2024년 5월 미국 질병예방통제센터(CDC)가 발표한 자료에 따르면, 2021년과 2022년 18세 이상 미국 성인 약 290만 명이 활동성 간질을 앓고 있으며, 이는 미국 성인 인구의 약 1%를 차지하는 것으로 밝혀졌습니다. 신경질환의 유병률이 증가함에 따라 디발프로엑스나트륨에 대한 수요는 확대될 것으로 예상됩니다.
디발프로엑스나트륨 시장의 주요 업체들은 환자의 순응도를 높이기 위해 서방형 정제와 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 이 정제는 유효성분이 시간이 지남에 따라 점진적으로 방출되도록 설계되어 투여 횟수가 적고 보다 안정적인 치료 효과를 기대할 수 있습니다. 예를 들어, 2022년 3월, 인도 제약사 유니켐 랩스(UniChem Laboratories)는 미국 식품의약국(FDA)으로부터 250mg과 500mg의 디발프로엑스나트륨 서방정 제네릭 의약품에 대한 승인을 받았습니다. 이 정제는 양극성 장애에 수반되는 급성 조증 및 조울증 에피소드의 치료제로 단독으로 또는 다른 치료제와 병용하여 편두통의 예방에 사용됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 디발프로엑스나트륨 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 디발프로엑스나트륨 시장 : 성장률 분석
세계의 디발프로엑스나트륨 시장 실적 : 규모와 성장, 2019-2024년
세계의 디발프로엑스나트륨 시장 예측 : 규모와 성장, 2024-2029년
, 2034년
세계의 디발프로엑스나트륨 전체 시장(TAM)
제6장 시장 세분화
세계의 디발프로엑스나트륨 시장 : 제품 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
태블릿
캡슐
서방정
기타 제품
세계의 디발프로엑스나트륨 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
정맥내
세계의 디발프로엑스나트륨 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
간질 치료
양극성 장애 관리
편두통 예방
신경 정신질환
기타 용도
세계의 디발프로엑스나트륨 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
기타 유통
세계의 디발프로엑스나트륨 시장, 정제 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
250mg정
500mg정
기타 강도 정제
세계의 디발프로엑스나트륨 시장, 캡슐 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
125mg 캡슐
250mg 캡슐
500mg 캡슐
기타 강도 캡슐
세계의 디발프로엑스나트륨 시장, 서방정 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
250mg 서방정
500mg 서방정
기타 강도 서방정
세계의 디발프로엑스나트륨 시장, 기타 제품 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구 용액
주사제
제7장 지역별·국가별 분석
세계의 디발프로엑스나트륨 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 디발프로엑스나트륨 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
디발프로엑스나트륨 시장 : 경쟁 구도
디발프로엑스나트륨 시장 : 기업 개요
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bausch Health Companies Inc.
Aurobindo Pharma Limited
Hikma Pharmaceuticals Public Limited Company
Amneal Pharmaceuticals Inc.
Lupin Limited
Zydus Lifesciences Limited
Alkem Laboratories Limited
Alembic Pharmaceuticals Limited
Supernus Pharmaceuticals Inc.
Strides Pharma Science Limited
Upsher-Smith Laboratories LLC
Ajanta Pharma Limited
Ishita Active Pharmaceutical Ingredients
Varahi International
Roaq Chemicals Private Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
디발프로엑스나트륨 시장 2029년 : 새로운 기회를 제공하는 국가
디발프로엑스나트륨 시장 2029년 : 새로운 기회를 제공하는 부문
디발프로엑스나트륨 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Divalproex sodium is a prescribed drug used to treat various neurological and psychiatric conditions. It is a combination of sodium valproate and valproic acid, which function by boosting the levels of gamma-aminobutyric acid (GABA) in the brain. GABA is a chemical that helps decrease excessive nerve activity. By stabilizing the brain's electrical signals, this medication promotes mental and neurological equilibrium.
Divalproex sodium is available in several forms, including tablets, capsules, extended-release tablets, and more. Tablets are solid oral dosage forms that contain the active ingredients, pressed into a specific shape for easy administration. It can be taken orally or intravenously and is used to treat conditions including epilepsy, bipolar disorder, migraine prevention, and neuropsychiatric disorders. The drug is available through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.
The divalproex sodium market research report is one of a series of new reports from The Business Research Company that provides divalproex sodium market statistics, including divalproex sodium industry global market size, regional shares, competitors with a divalproex sodium market share, divalproex sodium market segments, market trends and opportunities, and any further data you may need to thrive in the divalproex sodium. This divalproex sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The divalproex sodium market size has grown strongly in recent years. It will grow from $1.83 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth observed during the historical period can be credited to several factors, including increased healthcare spending, the expansion of pharmaceutical distribution networks, a rising demand for outpatient and home-based treatments, government reimbursement and insurance assistance, and a growing need for chronic disease management.
The divalproex sodium market size is expected to see strong growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth anticipated during the forecast period can be attributed to the rising prevalence of epilepsy, the increasing incidence of bipolar disorder, higher diagnosis rates of migraine disorders, a growing elderly population susceptible to neurological conditions, and expanded access to healthcare. Key trends in this period include advancements in drug formulation methods, increased research on central nervous system (CNS) disorders, innovations in drug delivery systems, enhanced diagnostic tools for epilepsy and bipolar disorders, and the development of biomarkers for targeted treatments.
The increasing prevalence of neurological disorders is expected to drive the growth of the divalproex sodium market in the future. Neurological disorders are conditions that affect the brain, spinal cord, or nerves, leading to impairments in function and symptoms such as muscle weakness, seizures, or cognitive difficulties. As life expectancy rises, the aging population becomes more susceptible to conditions including Alzheimer's and Parkinson's, which tend to develop later in life. Divalproex sodium plays a crucial role in managing neurological disorders by stabilizing electrical activity in the brain, preventing seizures, and controlling mood swings, which are common in conditions including epilepsy and bipolar disorder. For example, data from the Centers for Disease Control and Prevention (CDC) in May 2024 revealed that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2021 and 2022, accounting for about 1% of the adult population in the U.S. As the prevalence of neurological disorders rises, the demand for divalproex sodium is expected to grow.
Key players in the divalproex sodium market are concentrating on developing innovative solutions, such as extended-release tablets, to improve patient compliance. These tablets are designed to release their active ingredient gradually over time, enabling less frequent dosing and providing more consistent therapeutic effects. For example, in March 2022, Unichem Laboratories, a pharmaceutical company based in India, received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Divalproex Sodium extended-release tablets in 250 mg and 500 mg dosages. These tablets are used to treat acute manic or mixed episodes associated with bipolar disorder, both as a standalone treatment and in combination with other therapies, as well as for preventing migraine headaches.
In June 2024, Lotus Pharmaceuticals, a pharmaceutical company based in Taiwan, acquired the Thailand business and commercial operations of Teva Pharmaceuticals for an undisclosed amount. Following the acquisition, Lotus will assume responsibility for marketing and selling Teva Pharma Thailand's current product portfolio, which will become a wholly owned subsidiary of Teva. This acquisition will allow Lotus to expand its presence in Thailand by adding respiratory and ophthalmic products to its offerings and growing its local workforce to approximately 100 employees. The move will enhance Lotus's ability to reach more hospitals and pharmacies in the region. Teva Pharmaceuticals is an Israel-based manufacturer of divalproex sodium.
Major players in the divalproex sodium market are AbbVie Inc., Sanofi S.A., Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals Public Limited Company, Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Supernus Pharmaceuticals Inc., Strides Pharma Science Limited, Upsher-Smith Laboratories LLC, Ajanta Pharma Limited, Ishita Active Pharmaceutical Ingredients, Varahi International, Roaq Chemicals Private Limited, and MSN Laboratories Private Limited.
North America was the largest region in the divalproex sodium market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in divalproex sodium report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the divalproex sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The divalproex sodium market consists of sales of valproic acid oral solution, carbamazepine tablets, and lamotrigine tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Divalproex Sodium Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on divalproex sodium market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for divalproex sodium ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The divalproex sodium market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Divalproex Sodium Market Characteristics
3. Divalproex Sodium Market Trends And Strategies
4. Divalproex Sodium Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Divalproex Sodium Growth Analysis And Strategic Analysis Framework
5.1. Global Divalproex Sodium PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Divalproex Sodium Market Growth Rate Analysis
5.4. Global Divalproex Sodium Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Divalproex Sodium Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Divalproex Sodium Total Addressable Market (TAM)
6. Divalproex Sodium Market Segmentation
6.1. Global Divalproex Sodium Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
Extended-Release Tablets
Others Products
6.2. Global Divalproex Sodium Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
6.3. Global Divalproex Sodium Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epilepsy Treatment
Bipolar Disorder Management
Migraine Prophylaxis
Neuropsychiatric Disorders
Other Applications
6.4. Global Divalproex Sodium Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distributions
6.5. Global Divalproex Sodium Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
250 Mg Tablets
500 Mg Tablets
Other Strength Tablets
6.6. Global Divalproex Sodium Market, Sub-Segmentation Of Capsules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
125 Mg Capsules
250 Mg Capsules
500 Mg Capsules
Other Strength Capsules
6.7. Global Divalproex Sodium Market, Sub-Segmentation Of Extended-Release Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
250 Mg Extended-Release Tablets
500 Mg Extended-Release Tablets
Other Strength Extended-Release Tablets
6.8. Global Divalproex Sodium Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Solution
Injectable Form
7. Divalproex Sodium Market Regional And Country Analysis
7.1. Global Divalproex Sodium Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Divalproex Sodium Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
